CD274 and adenocarcinoma: Separate subgroup analyses were performed in relation to the type of study (RCTS vs. other studies), quality score (excluding trials of low quality), comparators (RT vs. ICI alone), population (locally advanced NSCLC vs. metastatic NSCLC), rate of PD-L1 < 1% (<20% vs. >20%) and rate of adenocarcinoma (<75% vs. >75%.